Skip to content

GMR方案公司

US · GMRS #3693 按市值排名 上市于 2026
10.00 -0.39 -3.75%
实时 - 追踪5344个代码 - 心跳于440秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 0.69 低于历史水平 第12百分位
5年平均 3.59 · 在Medical Care Facilities中排名第5/40
市盈率 -7.21 低于历史水平 第30百分位
5年平均 11.02 · 前瞻 1.49
市销率 0.09 低于历史水平 第11百分位
5年平均 0.16 · 前瞻 0.09 · 在Medical Care Facilities中排名第3/50

同业对比 Medical Care Facilities

公司 市值 市盈率(TTM) 市净率 股息率
GMR方案公司 (GMRS) 540.22M -7.14 0.68 0.00%
HCA Healthcare (HCA) 99.34B 15.39 -14.96 0.65%
Tenet Healthcare (THC) 21.52B 10.33 4.62 0.00%
Encompass Health (EHC) 12.61B 20.83 4.86 0.59%
DaVita (DVA) 11.95B 15.44 -15.62 0.00%
Fresenius Medical Care (FMS) 11.80B 11.90 0.84 3.85%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值14.75 经济护城河None 不确定性High

当前股价低于晨星合理价值估算47.5%。

合理价值

GMR Solutions Inc earns a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 32% discount to our quantitative fair value estimate of $14.75 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 147.7% ranks in the top 20% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

The company's balance sheet is an additional encouraging factor. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. The firm's EBITDA/interest coverage ratio of 2.6, a core component of leverage, ranks in the bottom 30% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. This characteristic further promotes our favorable price/fair value ratio.

经济护城河

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the company's weak financial health rating could portend bankruptcy risk if economic conditions weaken.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

GMR方案公司 讨论区 0 条评论

发表评论